CatalystWireBeta

OXB confirms partnership with Aura Biosciences

In brief · summary, not quotable

OXB enters manufacturing partnership with Aura Biosciences to support Phase 3 development of oncology candidate belzupacap sarotalocan.

Full announcement

Select text to share a quote on X · sign in to keep highlights & notes in your OXB notes

OXB confirms partnership with Aura Biosciences supporting Phase 3 development and future commercial supply of lead oncology candidate

 Partnership established earlier this year supports Aura’s Phase 3 virus-like drug conjugates (VDC) client programme and preparations for potential future commercial supply

 Programme builds on OXB’s extensive track record in process characterisation, PPQ and commercial-scale manufacturing

 Programme is supported from OXB’s FDA-approved commercial-scale facility in Durham, North Carolina

Oxford, UK – 17 November 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today confirm its manufacturing and supply partnership with Aura Biosciences, Inc. (“Aura”) (NASDAQ: AURA), a biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers. OXB is supporting late-stage development and manufacturing activities for Aura’s lead virus-like drug conjugate candidate, belzupacap sarotalocan (bel-sar), as Aura advances the programme through Phase 3 development and prepares for potential future commercial supply. Aura recently announced the partnership and its manufacturing strategy in its Q3 corporate update.

Aura’s programme is being supported from OXB’s process and analytical development facility in Bedford, Massachusetts, and FDA-approved, commercial-scale viral vector manufacturing facility in Durham, North Carolina, which brings drug substance and fill and finish capabilities together on one site. OXB has initiated technical transfer in preparation for process performance qualification (PPQ) and commercial production. Together, these activities will support Aura’s manufacturing readiness for late-stage clinical development, potential future regulatory filings and commercialisation.

This partnership reflects OXB’s leading position in the space, drawing on more than 30 years of viral vector process development, analytical and GMP manufacturing experience into clinical and commercial stages.

Dr. Sebastien Ribault, Chief Business Officer of OXB, commented: “As Aura advances bel-sar through Phase 3 development, a well-characterised and robust manufacturing process is critical. OXB brings extensive experience supporting complex viral vector programmes through process characterisation, PPQ and towards commercialisation. Supporting this promising candidate from our site in Durham, North Carolina, gives Aura experienced late-stage process and manufacturing teams at a site built for commercial-scale production. This also represents an exciting opportunity for OXB to step into VDC manufacturing, an adjacent segment that sits close to our core viral vector expertise and this partnership demonstrates our ability to provide a world-class service offering in this area.”

Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.

Share this quote

Quote card
Post on X WhatsApp Download image

The link opens this announcement with the quote highlighted. Quotes are checked against the original text.

Add a note